...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European urology >Re: Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis.
【24h】

Re: Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis.

机译：回复：我们是否应该筛查高危人群的膀胱癌？每生命年节省的成本分析。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The authors use Markov modeling to assess cancer-related costs and efficacy of screening high-risk populations for bladder cancer with a urine-based marker. They used data from published studies of screening and marker performance to establish their model. They estimate that, in a population with a 4% incidence of bladder cancer, a gain of 3 life-years per 1000 subjects can be achieved at a cost savings of more than dollar100,000 for the population, if one assumes a 50% downstaging in the screened population from muscle-invasive to non-muscle-invasive cancer. There would still be cost efficacy as long as the cancer incidence is >1.6% and tumor markers cost < dollar 126, even with a low marker sensitivity (>=27%) and specificity (>=54%).
机译：作者使用马尔可夫模型来评估与癌症相关的成本和使用尿液标记物筛查高危人群膀胱癌的功效。他们使用来自已发表的筛选和标记物性能研究的数据来建立模型。他们估计，在膀胱癌发病率为4％的人群中，如果假设降级50％，则每千名受试者可以实现3个生命年的收益，而为该人群节省的成本超过100,000美元。筛查人群中从肌肉浸润癌到非肌肉浸润癌。只要癌症的发生率> 1.6％，且肿瘤标志物的价格<126美元，即使标志物的敏感性低（> = 27％）和特异性低（> = 54％），仍然具有成本效益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号